2. Academic Validation
  3. Enhancing Osteosarcoma Therapy through Aluminium Hydroxide Nanosheets-Enabled Macrophage Modulation

Enhancing Osteosarcoma Therapy through Aluminium Hydroxide Nanosheets-Enabled Macrophage Modulation

  • Int J Pharm. 2023 Dec 1:123640. doi: 10.1016/j.ijpharm.2023.123640.
Min Cheng 1,  Yi Jiang 1,  Ying Wang 1,  Yilun Wu 1,  Yishen Zhu 2
Affiliations

Affiliations

  • 1 College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
  • 2 College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China. Electronic address: [email protected].
PMID: 38043749 DOI: 10.1016/j.ijpharm.2023.123640
Abstract

Chemotherapy in osteosarcoma treatment has long been stagnating, leaving challenges in the treatment of patients with metastatic and recurrent osteosarcoma. Modulation of macrophages in the tumour microenvironment offers great opportunities to elicit a durable antitumour effect. Here, we employed aluminium hydroxide nanosheets (nAl) to co-deliver the chemotherapy drug doxorubicin (DOX) and immune modulator zoledronic acid (ZA). The hexagon nAl was obtained by a facile approach, with a high positive surface charge for the loading of ZA. With 37% and 8.5% payloads to ZA and DOX, the formed nAl/ZD showed efficient cell growth inhibition to LM8 osteosarcoma cells, and preferential M1 polarization induction to RAW 264.7 macrophage cells. Furthermore, enhanced antitumour effect was observed with nAl/ZD-enabled macrophage activation in the LM8/RAW 264.7 co-culture model. Our results may inspire new treatment strategies for osteosarcoma.

Keywords

Aluminium hydroxide; Combination therapy; Macrophage modulation; Osteosarcoma therapy; Zoledronic acid.

Figures
Products